Get notified when LLY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Emgality Patent Reversal (worsened) — Federal Circuit reversed trial-court victory, reinstating Teva's patent claims and triggering a Q1 2026 charge.
- Amp Litigation Verdict Affirmed (worsened) — Seventh Circuit affirmed adverse jury verdict in Medicaid-pricing qui tam, triggering a charge; en banc rehearing denied, Supreme Court petition filed.
- Incretin Product Liability Expansion (worsened) — Litigation now covers Zepbound, split into two MDLs (GI injuries, NAION vision claims), and added Canadian class actions.
- Texas Medicaid Qui Tam Escalation (worsened) — Relator expanded claims from 3 to 15 products and added State of Texas as party in new lawsuit filed August 2025.
- 340b Mosaic Health Reversal (worsened) — Second Circuit reversed dismissal, reviving antitrust and unjust-enrichment claims; Supreme Court petition filed March 2026.
Lilly Q1 revenue +56% to $19.8B on incretin surge; Emgality patent loss, AMP verdict affirmed
Filed April 30, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 1, 2025 · ~2 min read
Key Changes
-
high
Federal Circuit reversed Emgality patent trial win, reinstating Teva's infringement claims and triggering a Q1 charge; Seventh Circuit affirmed adverse AMP jury verdict, also triggering a charge, with Supreme Court petition filed March 2026.
Legal Proceedings: Emgality patent, AMP litigation verify on EDGAR → -
high
Incretin product liability expanded to two MDLs (GI injuries, NAION vision claims), now covering Zepbound alongside Mounjaro/Trulicity; Texas Medicaid qui tam escalated from 3 to 15 products with State of Texas joining as party.
Legal Proceedings: Incretin MDL, Texas qui tam verify on EDGAR → -
high
Mounjaro/Zepbound now 65% of total revenue ($12.8B combined); new U.S. government pricing agreements lower Medicaid prices and launch Medicare GLP-1 Bridge Program (July 2026–Dec 2027), with uncertain uptake and policy impact.
MD&A: Revenue concentration, pricing agreements verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (GTM 10-Q) is open in full — no account needed.
Partner
Trade LLY commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 26, 2026 · How we verify